NASDAQ: ABUSArbutus Biopharma Corp Stock
$4.36+0.02 (+0.46%)
Updated Aug 3, 2026
ABUS Price
$4.36
Fair Value Price
-$2.95
Market Cap
$861.26M
52 Week Low
$3.30
52 Week High
$5.38
P/E
5.19x
P/B
3.31x
P/S
4.56x
PEG
N/A
Dividend Yield
N/A
Revenue
$191.45M
Earnings
$160.72M
Gross Margin
100%
Operating Margin
84%
Profit Margin
84%
Debt to Equity
0.07
Operating Cash Flow
-$34M
Beta
0.96
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ABUS Overview
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ABUS's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +17.17% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ABUS
Ranked#18 of 461
Ranked#18 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $11.04 | A | |
| $8.13 | A | |
| $112.80 | A |
Be the first to know about important ABUS news, forecast changes, insider trades & much more!
ABUS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ABUS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABUS ($4.36) is overvalued by 247.63% relative to our estimate of its Fair Value price of -$2.95 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ABUS ($4.36) is not significantly undervalued (247.63%) relative to our estimate of its Fair Value price of -$2.95 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ABUS is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ABUS due diligence checks available for Premium users.
Valuation
ABUS fair value
Fair Value of ABUS stock based on Discounted Cash Flow (DCF)
Price
$4.36
Fair Value
-$2.95
Undervalued by
247.63%
ABUS ($4.36) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ABUS ($4.36) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ABUS is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ABUS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
5.19x
Industry
19.81x
Market
14.82x
ABUS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ABUS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ABUS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.31x
Industry
5.21x
ABUS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABUS's financial health
Profit margin
Revenue
$179.1M
Net Income
$169.7M
Profit Margin
94.7%
ABUS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ABUS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$277.2M
Liabilities
$17.0M
Debt to equity
0.07
ABUS's short-term assets ($277.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABUS's short-term assets ($277.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABUS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ABUS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.1M
Investing
$2.2M
Financing
$11.6M
ABUS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABUS vs Biotech Stocks
Arbutus Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.